Research on injection in ahmedabad

EXECUTIVE SUMMERY

Claris Lifesciences Ltd., a pharmaceutical company having its presence in 76 countries is

based in Ahmedabad, Gujarat, India. It primarily concentrates on the parenteral drugs and

drug delivery system. Having established its presence since 1991, it has achieved market

leadership in many parental

My project as Claris was concerned with finding out the potential of Injectable molecule

which Claris wanted to introduce in its generic Injectable segment. I worked under the

marketing department where in at the onset I was given a thorough orientation of the

organization, its unique business model where in individual entrepreneurship and corporate

governance go hand in hand, some of their well established products, their work culture and

rules and regulations were informed to me.

My work comprised of preparation of questionnaire, defining my target market, sample size.

My target market comprised of Chemists and Medical shop owners where in I required one to

one interaction hence by collecting information. Further for the collection of the secondary

information I referred various company sources, articles of Pharma industry and drug

directories.

During the course of my project I had an encouraging practical experience and a chance to

learn the practical aspect of the pharmaceutical industry and the corporate world on the

whole.

Putting my experiences in to words, “Business school is about theory while Business is all

about action.”

1

OBJECTIVES

To find out the opportunity for new injectable drugs which Company do not have and for

which,

There is high future potential in mid to long term and currently less

competitors.

There is good movement in injectable drugs market.

Acceptability is high

To find out new or expected strength for the existing injectable drugs

as well as new drugs.

Competitor scenario

2

INTERODUCTION

Pharmaceutical industry

Pharmaceutical Industry in India is one of the largest and most advanced among the

developing countries. It provides employment to millions and ensures that essential drugs at

affordable prices are available to the vast population of India. Indian Pharmaceutical Industry

has attained wide ranging capabilities in the complex field of drug manufacture and

technology. From simple pain killers to sophisticated antibiotics and complex cardiac

compounds, almost every type of drug is now made indigenously.

Indian Pharma Industry is playing a key role in promoting and sustaining development in the

vital field of medicines. Around 70% of the country's demand for bulk drugs, drug

intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and vaccines is

met by Indian pharmaceutical industry. A number of Indian pharmaceutical companies

adhere to highest quality standards and are approved by regulatory authorities in USA and

UK.

Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units and

is very top heavy. The leading 250 pharmaceutical companies control 70% of the market with

market leader holding nearly 7% of the market share. There are also 5 Central Public Sector

Units that manufacture drugs. These units produce complete range of pharmaceuticals, which

include medicines ready for consumption by patients and about 350 bulk drugs, i.e.,

chemicals having therapeutic value and used for production of pharmaceutical formulations.

India is largely self-sufficient in case of formulations. More than 85% of the formulations

produced in the country are sold in the domestic market. Some life saving, new generation

under-patent formulations are imported, by MNCs, which they market in India. Over 60% of

India's bulk drug production is exported. The balance is sold locally to other formulators.

Pharmaceutical Industry in India has been de-licensed and industrial licensing for most of the

drugs and pharmaceutical products has been done away with. Manufacturers are now free to

produce any drug duly approved by the Drug Control Authority. Indian pharmaceutical

industry got a major boost with the signing of General Agreement on Tariffs and Trade in

January 2005 with which India began recognizing global patents. After recognizing the

3

global patent regime the Indian Pharma market became a sought after destination for foreign

players.

India holds the lion's share of the world's contract research business as activity in the Pharma

market continues to explode in this region. Over 15 prominent contract research

organizations (CROs) are now operating in India attracted by her ability to offer efficient

R&D on a low-cost basis. Thirty five per cent of business is in the field of new drug

discovery and the rest 65 per cent of business is in the clinical trials arena. India offers a huge

cost advantage in the clinical trials domain compared to Western countries. The cost of hiring

a chemist in India is one-fifth of the cost of hiring a chemist in the West.

The future of Indian pharmaceutical sector looks extremely positive. Indian Pharma

companies are vying for the branded generic drug space to register their global presence.

Several Indian pharmaceutical companies have acquired companies in the US and Europe and

many others are raising funds to do so. For example, Ranbaxy acquired Romania's Terapia,

Ethimed NV of Belgium and GSK's generic business Allen SpA in Italy. Dr Reddy's acquired

German generic drug maker Betapharm. Companies like Glenmark Pharma, Lupin,

Aurobindo and Jubilant Organosys are on the lookout for lucrative acquisitions.

(Source:www.worldpharmanews.com)

4

Injectable Drug Market in India

In India , the injectable market has shown significant growth with large potential for more.

The moving annual total in the domestic market for injectables was Rs 5,631.10 crores for the

year-ended-December-2008.

Injectable antibiotics market in particular has witnessed strong growth, the injectable

antibiotics market in India has shown robust growth in the last 4-5 years mainly because of

the introduction of high-end antibiotic brands at higher prices and the subsequent

proliferation of generic versions of many of the leading high-end antibiotic brands.

The domestic injectable antibiotics market is worth $425 million and has been growing at a

CAGR of 21 per cent in the last three years. The domestic market is likely to slow down a bit

and the expected CAGR in the next 5 years is likely to be 16 per cent taking the estimated

market value of injectable to $900 million.

The generic injectables segment that most Indian companies focus on is getting a boost from

government-sponsored healthcare programmes and private insurers. Injectables using small

molecules represent 25% of the market and are estimated to be at $35 billion of world

market, growing at 11%. Most generic injectables use small molecules which comprise 65%

of sales and are focused on oncology and cardiovascular. Monoclonal antibodies and

bioengineered vaccine injectables are expected to grow faster than the market.

(Source:www.pharmaworld.com)

5

Non-prescription drugs

They may be sold “over the counter” since they are judged to be safe for use without medical

supervision.

Prescription drugs

They are considered to be unsafe for use except under medical supervision, therefore ,they

are dispensed only on a physician’s prescription.

GENERIC DRUGS

A generic drug is a drug which is produced and distributed without patent protection. The

generic drug may still have a patent on the formulation but not on the active ingredient.

A generic must contain the same active ingredients as the original formulation. According to

the U.S. Food and Drug Administration (FDA), generic drugs are identical or bioequivalent

to the brand name counterpart with respect to pharmacokinetic and pharmacodynamic

properties. By extension, therefore, generics are identical in dose, strength, route of

administration, safety, efficacy, and intended use.

In most cases, generic products are available once the patent protections afforded to the

original developer have expired. When generic products become available, the market

competition often leads to substantially lower prices for both the original brand name product

and the-generic-forms.

BRANDED DRUGS

A Branded Drug has a trade name and is drug manufactured by a well established

pharmaceutical company, protected by a patent. It cannot be produced or sold by any other

company. A brand name will be simpler than the generic name.

(Source: Elements of Pharmacology book)

6

WHAT IS INJECTABLE DRUG?

An Injection (often referred to as a "shot") is an infusion method of putting liquid into the

body, usually with a hollow needle and a syringe which is pierced through the skin to a

sufficient depth for the material to be forced into the body. An injection follows a Parenteral

route of administration, that is, administered other than through the digestive tract

Administration involving a needle or syringe occurs with several drug routes. These routes

are referred to as parentaral. Care must be taken to maintain asepsis with all injections and

injection sites. Intramuscular medications are injected into the muscle. All intramuscular

injections involve the practice of land marking, or identifying anatomical markers that

indicate the correct injection site and avoid damage to bone or nerves. Subcutaneous

injections are administered under the skin. Insulin is a common medication that is usually

given subcutaneously. Intradermal medications are used much less frequently than

subcutaneous or intramuscular injections. They are injected into the skin. Intravenous

medications are given through an intravenous line into the vein. These medications may be

mixed with a large amount of solution that is being infused, given in a small solution through

a port in the intravenous tubing (bolus), or attached in smaller infusion containers to the

larger infusion.

In all cases of administration with a needle or syringe, rotation of injection sites is required to

prevent damage to tissue. It is also important that the size of the needle is selected based on

the thickness of the medication to be given and the depth of the injection, while maximizing

the patients level of comfort during insertion. Needle sticks with contaminated needles are a

hazard to both health professional and patient. Care is taken to dispose of needles and

syringes rapidly in impervious containers. Protective systems that sheath the needle after use

are commonly used to prevent inadvertent needle sticks. Injectable or Intravenous (IV)

therapy is very common practice in hospitals; up to 80% of Hospitalized patients receive IV

therapy at some point during their stay in the hospital. Fluids, medications, blood and blood

products and nutrition can all be given by the IV Route which can be either peripheral or

central. IV fluids are administered to restore Hemodynamic stability and to restore fluid and

electrolyte balance. Hence, they are potentially life-saving in many situations.

(Source: www.pharmafocussia.com)

7

TYPE OF INJECTIONAL ROUTE

Intravenous (into a vein) e.g. many drugs, total Parenteral nutrition

Intra-arterial (into an artery), e.g. vasodilator drugs in the treatment of vasospasm and

thrombolytic drugs for treatment of embolism

Intramuscular (into a muscle), e.g. many vaccines, antibiotics, and long-term

psychoactive agents. Recreationally the colloquial term 'muscling' is used.

Intracerebral (into the cerebrum) direct injection into the brain. Used in experimental

research of chemicals and as a treatment for malignancies of the brain.

Intracardiac (into the heart), e.g. adrenaline during cardiopulmonary resuscitation (no

longer commonly performed)

Subcutaneous (under the skin), e.g. insulin, a slang term for this method of

administration is skin popping (usually done with recreational drugs)

Intraosseous infusion (into the bone marrow) is, in effect, an indirect intravenous

access because the bone marrow drains directly into the venous system. This route is

occasionally used for drugs and fluids in emergency medicine and pediatrics when

intravenous access is difficult.

Intradermal, (into the skin itself) is used for skin testing some allergens, and also for

mantoux test for Tuberculosis

Intrathecal (into the spinal canal) is most commonly used for spinal anesthesia and

chemotherapy

Intraperitonial, (infusion or injection into the peritoneum) e.g. peritoneal dialysis

Intravesical infusion is into the urinary bladder.

(Source: Elements of Pharmacology book)

8

About Claris Lifesciences Ltd.

VISION

To be one of the worlds’ leading and most admired pharmaceutical companies in the global

Generics industry.

BUSINESSES

• Anesthesia

• Plasma Volume Expanders & Blood Products

• Clinical Nutrition

• Renal and Transplant

• Oncology

• Anti infectives

• Infusion therapy

• Pharmaceutical Generics

MARKET PRESENCE:

• Presence in 76 countries across Latin America, Europe, Gulf, Africa, CIS, Central

Asia and Asia- Pacific

• Subsidiary companies, laboratories, office infrastructure

• Grass root marketing and brand building

• Supplier to aid agencies

9

MANUFACTERING

• World class facilities designed to manufacture aqueous and lipid emulsion products

across various drug delivery systems.

• Bags

PVC/Non-PVC – single bags

Multi-chamber bags

Double bag systems

• Glass containers

Bottles

Vials

Ampoules

• Aseptic manufacturing

Liquid form

Oral Form

New /Future technologies

• Lyophilization

• Prefilled syringes

Glass

• Liposomal technology

Cytotoxic

• Soft gelatin capsules

• Blow-Fill-Seal.

10

Emotional Pharmacopoeia

The company's philosophy is based on Emotional Pharmacopoeia. A pharmacopoeia

is a document, which gives various guidelines about making a product. Different countries

like USA, UK, INDIA have their own pharmacopoeia. We have gone one step ahead and

made an emotional pharmacopoeia, which means every time you make, release or market a

product, the first question you should ask is “Can we use it on our dearest ones?” If your

heart says yes, with 100% confidence about its quality, you can accept the product and make

it available to save lives of patients across the world.

(Source: clarislifesciences.com)

11

RESEARCH DESIGN

This design consist of sample of Retailers in East zone of Ahmedabad, to understand the

movement of Injectable molecules.

Sample Selection :Randomly on convenience basis.

Sample Size : 137

Sampling procedure : Area sampling (Cluster sampling)

Data Collection Methods

Primary Data : By one-to-one discussion and questionnaire with retailers.

Secondary data : Internet, Company sources, Magazines.

Research Instruments : Questionnaire

12

Scheduling

The research is completed within the time span of eight weeks starting from 20th May .The

schedule is presented here week wise.

Weeks Starting date Work done

1st 20th May Training about the Products

2nd 27th May Designing the questionnaire

3rd 3rd June Survey

4th 10th June Survey

5th 17th June Survey

6th 24rd June Survey

7th 1st July Analysis of the data

8th 8th July Presenting the results

13

DATA ANALYSIS AND FINDING (BASED ON POTENTIAL)

Molecules AVERAGE

MRPs

Quantity

(Monthly)

POTENTIAL(Rs.)

Amoxicillin + Clavulanic Acid 141.90 1647.00 220472.62

Amikacin Sulphate 61.27 2677.00 161506.23

Pantoprazole 58.42 1590.00 92967.00

Ondansetron 26.59 3381.00 89129.48

Multivitamin Infusion 13.79 3940.00 54146.16

Diclofenac Sodium 9.74 4210.00 41084.25

Tramadol 27.98 830.00 23266.38

Vitamin B-Complex 4.24 4455.00 18955.85

Amoxicillin 19.02 945.00 18675.00

Ranitidine 3.23 5475.00 17439.15

Ampicillin 250 mg +

Cloxacillin 250 mg

13.47 1355.00 16886.50

Calcium Gluconate 34.67 350.00 12280.00

Ampicillin 1 g + Salbactum

0.5 g

109.44 109.00 11902.50

Gentamicin 7.14 1565.00 11483.43

Frusemide 29.98 353.00 10550.76

Dexamethasone 7.14 1012.00 7245.16

Artesunate 217.00 25.00 5285.00

14

Atropin Sulphate 10.92 427.00 4557.33

Metoclopramide 6.78 505.00 3410.75

Chloroquine Phosphate 5.07 574.00 2838.45

Matoclopramide 6.70 182.00 1244.80

Daizapam 5.00 5.00 25.00

*Potential is the product of average MRP of different brands for particular molecule and the

quantity sold (monthly) for that molecule.

15

5 MOLECULES WITH HIGEST POTENTIAL

Molecules POTENTIAL(Rs.) % SHARE

Amoxicillin + Clavulanic Acid 220472.62 36 %

Amikacin Sulphate 161506.23 26 %

Pantoprazole 92967.00 15 %

Ondansetron 89129.48 14 %

Multivitamin Infusion 54146.16 9%

Graph shows the relation between molecules and their potentials. Amoxicillin + Clavulanic

acid has the highest potential while other molecules follow it up.

16

Graph shows the percentage share of 5 Molecules having the highest potential. Amoxicillin +

Clavulanic acid has the highest percentage share while other molecules follow it up.

17

MOLECULES – AREA - TOTAL

Sr.No Molecules Name of Area Potential

(Rs.)

1 Amoxicillin + Clavulanic Acid Meghani nagar 108811.67

Maninagar 68409.00

C.T.M 19327.95

Kankaria 16340.00

BAPUNAGAR 6004.00

VASTRAL 1580.00

Amoxicillin + Clavulanic Acid Total 220472.62

2 Amikacin Sulphate Meghani nagar 58442.50

Maninagar 40439.43

BAPUNAGAR 35877.50

Kankaria 8139.80

ODHAV 7367.50

C.T.M 4762.50

Amraiwadi 3492.50

VASTRAL 2984.50

Amikacin Sulphate Total 161506.23

3 Pantoprazole Meghani nagar 38045.00

Maninagar 34528.00

BAPUNAGAR 8656.55

Kankaria 6591.35

18

C.T.M 2234.35

ODHAV 1490.00

Amraiwadi 1421.75

Pantoprazole Total 92967.00

4 Ondansetron Maninagar 25766.00

BAPUNAGAR 24957.83

Meghani nagar 24899.00

C.T.M 4765.00

Kankaria 3529.50

VASTRAL 1979.65

ODHAV 1642.50

Amraiwadi 1590.00

Ondansetron Total 89129.48

5 Multivitamin Infusion Meghani nagar 19966.48

Maninagar 19578.43

BAPUNAGAR 5173.80

Amraiwadi 3544.98

Kankaria 3132.07

VASTRAL 1377.50

ODHAV 772.90

C.T.M 600.00

Multivitamin Infusion Total 54146.16

19

20

AREA – MOLECULES - POTENTIAL

AREA MOLECULES POTENTIAL (Rs.)

Amraiwadi Multivitamin Infusion 3544.98

Amikacin Sulphate 3492.50

Ondansetron 1590.00

Pantoprazole 1421.75

Ranitidine 1089.00

Diclofenac Sodium 1087.50

Frusemide 793.20

Vitamin B-Complex 727.50

Dexamethasone 320.85

Metoclopramide 138.00

Chloroquine Phosphate 68.56

21

Potential of Molecules in Amraiwadi area. In which Multivitamin Infusion has the

highest potential while other molecules follow it up.

Potential of different molecules in Bapunagar area.

AREA MOLECULESPOTENTIAL

(Rs.)

BAPUNAGAR

Amikacin Sulphate 35877.50Ondansetron 24957.83Pantoprazole 8656.55Diclofenac Sodium 8055.00Tramadol 6698.13Amoxicillin + Clavulanic Acid 6004.00Multivitamin Infusion 5173.80Ranitidine 4592.05Vitamin B-Complex 3090.00Artesunate 1120.00Dexamethasone 863.81Metoclopramide 749.50Ampicillin 250 mg + Cloxacillin 250 mg 672.50Amoxicillin 595.00Calcium Gluconate 360.00Gentamicin 345.95Chloroquine Phosphate 233.40Atropin Sulphate 75.00Daizapam 25.00

22

Potential of Molecules in Bapunagar area.Amikacin Sulphate has the highest potential while

other molecules follow it up.


C.T.MAmoxicillin + Clavulanic Acid 19327.95

Ondansetron 4765.00


Amoxicillin 3120.00


Atropin Sulphate 900.00

Multivitamin Infusion 600.00

Ranitidine 495.00

Ampicillin 250 mg + Cloxacillin 250 mg 285.00

Potential of different molecules in C.T.M area.

23

Potential of Molecules in C.T.M area.Amoxicillin + Clavulanic acid has the highest potential

while other molecules follow it up.

Potential of different molecules in Kankaria area.


Kankaria

Amoxicillin + Clavulanic Acid 16340.00



Ondansetron 3529.50



Amoxicillin 1700.00


Tramadol 847.50

Frusemide 753.00

Ranitidine 733.70


Gentamicin 530.00




24


Potential of Molecules in Kankaria area. Amoxicillin + Clavulanic acid has the highest

potential while other molecules follow it up.

25

Potential of different molecules in Maninagar area.

AREA MOLECULES POTENTIAL(Rs.)

Maninagar




Ondansetron 25766.00



Ampicillin 1 g + Salbactum 0.5 g 8382.50

Calcium Gluconate 7140.00

Amoxicillin 7055.00

Tramadol 6841.75



Ranitidine 4774.80

Frusemide 4427.52

Gentamicin 3065.08




Artesunate 1120.00


26

Potential of different molecules in Meghani nagar area.


Meghani nagar




Ondansetron 24899.00




Tramadol 8314.00


Gentamicin 6989.00

Amoxicillin 6205.00


Ranitidine 4566.60


Frusemide 3372.24



Matoclopramide 1168.00



27

Potential of different molecules in Odhav area.


ODHAV


Artesunate 3045.00


Ondansetron 1642.50



Ranitidine 759.00

Frusemide 753.00



Tramadol 282.50




Gentamicin 62.90


28

Potential of molecules in Odhav area. Amikacin Sulphate has the highest potential while


Potential of different molecules in Vastral area.


VASTRAL


Ondansetron 1979.65




Gentamicin 490.50


Frusemide 451.80


Ranitidine 429.00


Tramadol 282.50





29

Potential of Molecules in Vastral area. Amikacin Sulphate has the highest potential while


MOLECULE – HOSPITALS - POTENTIALS

MOLECULE HOSPITALS POTENTIAL(Rs.

)

Amoxicillin+ Clavulanic

Acid

Civil Hos 108811.67

L.G.Hospital 71026.50

Doctor's House 19327.95

Doctor

House,R'St

13722.50

Kakdiya Hos 6004.00

Matruchhaya 1580.00

30

Hospital wise potential of Amoxicillin+Clavulanic Acid. Civil Hospital shows the highest

potential among all the hospitals.

Potential of Amikacin Sulphate in different Hospitals.

MOLECULE HOSPITALS POTENTIAL

(Rs.)

AMIKACIN

SULPHATE

Civil Hos 58442.50


Kakdiya Hos 35877.50

Doctor House,R'St 12056.53

Dr.House ODHAV 7367.50


Matruchhaya 2984.50

31

Hospital wise potential of Amikacin Sulphate. Civil Hospital shows the highest potential

among all the hospitals.

32

Potential of Pantoprazole in different Hospitals.

MOLECULE HOSPITALS POTENTIAL (Rs.)

Pantoprazole

Civil Hos 38045.00


Kakdiya Hos 8656.55




33

Hospital wise potential of Pantoprazole. Civil Hospital shows the highest potential among all

the hospitals.

34

Potential of Ondasetron in different Hospitals.


Ondansetron


Kakdiya Hos 24957.83

Civil Hos 24899.00


Doctor House, R'St 3862.00

Matruchhaya 1979.65


35

Hospital wise potential of Ondasetron. L.G. Hospital shows the highest potential among all

the hospitals.

Potential of Multivitamin Infusion in different Hospitals.


Multivitamin

Infusion


Civil Hos 19966.48

Kakdiya Hos 5173.80


Matruchhaya 1377.50



36

Hospital wise potential of Multivitamin Infusion. L.G.Hospital shows the highest potential

among all the hospitals.

37

Competitors’ Scenario

Sr.No. Molecules Brands Companies

1Amoxicillin +

Clavulanic Acid

Augmentin GSK

Boostim SVIZERA H. CARE

Clavam ALKEM

Moxclav REXCEL

2 Amikacin Sulphate

Mikacin ARISTO

Amizec ZEE LAB

Mikastar DISCOVERY

MANKIND

Amicin BIOCHEMIST

3 Pantoprazole

Pan 40 ALKEM

Pantodac CADILA

Pantop ARISTO

4 Ondansetron Emeset CIPLA

38

Ondem ALKEM

Periset IPCA

Vomikind MANKIND

Zofar SUN

Stean STRONCH

Vomiset INDI PHARMA

Ontic CORONA

5Multivitamin

Infusion

Eldervit ELDER

Vitcofol FDC

MVI USV

Optinuron LUPIN

Nurokind MANKIND

Nervic UNIMARCK

Nervizen UNIMARCK

39

40

Schemes for molecules in particular area and potential of Molecules under

that scheme :

Sr.No Molecules Name of Area Scheme POTENTIAL

(Rs.)

1 Amoxicillin +

Clavulanic Acid

Meghani nagar Net 8835.00

(No Scheme) 99976.67

Meghani nagar Total 108811.67

Maninagar Net 474.00


Maninagar Total 68409.00

C.T.M (No Scheme) 19327.95

C.T.M Total 19327.95

Kankaria (No Scheme) 16340.00

Kankaria Total 16340.00

BAPUNAGAR (No Scheme) 6004.00

BAPUNAGAR Total 6004.00

VASTRAL (No Scheme) 1580.00

VASTRAL Total 1580.00

Amoxicillin +

Clavulanic Acid Total

220472.62

2 Amikacin Sulphate Meghani nagar 1+1 5080.00

41

2+1 3337.50

3+1 3175.00

5+1 3810.00



Maninagar 10+2 3579.60

10+4 11294.20

5+1 6821.20

5+1/2 635.00



BAPUNAGAR 10+4 635.00

22+11 3810.00

3+1 952.50

5+1/2 1270.00



Kankaria 10+1 635.00

5+1/2 1789.80

(No Scheme) 5715.00


ODHAV 10+2 952.50

42

10+4 1587.50

11+10 1905.00

(No Scheme) 2922.50

ODHAV Total 7367.50

C.T.M 3+1 952.50

(No Scheme) 3810.00

C.T.M Total 4762.50

Amraiwadi 10+4 1270.00

(No Scheme) 2222.50

Amraiwadi Total 3492.50

VASTRAL 3+1 317.50

(No Scheme) 2667.00


Amikacin Sulphate

Total

161506.23

3 Pantoprazole

Meghani nagar (No Scheme) 38045.00


Maninagar (No Scheme) 34528.00



43

(No Scheme) 7467.85




C.T.M 5+1 284.35

(No Scheme) 1950.00

C.T.M Total 2234.35

ODHAV 5+1 870.00

(No Scheme) 620.00

ODHAV Total 1490.00

Amraiwadi (No Scheme) 1421.75


Pantoprazole Total 92967.00

4 Ondansetron


5+1 2510.00

9+1 1255.00






Meghani nagar 9+1 960.00

44



C.T.M 5+1 805.00

(No Scheme) 3960.00

C.T.M Total 4765.00



VASTRAL 10+4 287.50

4+1 113.25

5+1 1020.00

(No Scheme) 558.90


ODHAV 10+1 113.00

4+1 680.00

4+2 396.50

(No Scheme) 453.00

ODHAV Total 1642.50




5 Multivitamin Infusion Meghani nagar 10+1 387.50

45

20+1 1346.40

25+1 435.25




20+1 2470.50



BAPUNAGAR (No Scheme) 5173.80






VASTRAL (No Scheme) 1377.50


ODHAV (No Scheme) 772.90

ODHAV Total 772.90

C.T.M (No Scheme) 600.00

C.T.M Total 600.00

46

ANALYSIS AND FINDING (BASED ON VOLUME)

MOLECULES Quantity (Monthly)

Ranitidine 5475.00




Ondansetron 3381.00




Gentamicin 1565.00



Amoxicillin 945.00

Tramadol 830.00




Frusemide 353.00




Artesunate 25.00

Daizapam 5.00

47

Graph shows the relationship between molecules and quantity sold per month. Ranitidine has

the highest quantity sold while Vitamin B-Complex, Diclofenac Sodium, Multivitamin

Infusion, Ondasetron and others follow it up respectively.

48

5 MOST MOVEBLE MOLECULES (In terms of Quantity sold per month)

MOLECULES Sum of Quantity (Monthly)

Ranitidine 5475.00




Ondansetron 3381.00

Graph shows the relationship between molecules and quantity sold per month. Ranitidine has

the highest quantity sold while Vitamin B-Complex, Diclofenac Sodium, Multivitamin

Infusion, Ondasetron follow it up respectively.

49

Percentage share of Molecules in terms of Quantity (Monthly). Ranitidine has the highest

percentage (In terms of Quantity) while Vitamin B-Complex, Diclofenac Sodium,

Multivitamin Infusion, Ondasetron and others follow it up respectively.

50

MOLECULES – AREA - QUANTITY

MOLECULE AREA QUANTITY (MONTHLY)

Ranitidine

Maninagar 1535.00


BAPUNAGAR 1430.00

Amraiwadi 330.00

ODHAV 230.00

Kankaria 230.00

C.T.M 150.00

VASTRAL 130.00

Ranitidine Total 5475.00

Quantity sold (monthly) of Ranitidine in different areas. Highest quantity of Ranitidine is

sold in Maninagar while Meghani nagar, Bapunagar, Amraiwadi and other areas follow it up

respectively.

51

Total quantity of Vitamin B-Complex in different areas.


Vitamin B-Complex


Maninagar 1285.00

BAPUNAGAR 735.00

Kankaria 245.00

Amraiwadi 180.00

ODHAV 120.00

VASTRAL 110.00

Vitamin B-Complex Total 4455.00

52

Quantity sold (monthly) of Vitamin B-Complex in different areas. Highest quantity of

Vitamin B-Complex is sold in Meghani nagar while Maninagar, Bapunagar, Kankaria and

other areas follow it up respectively.

Total quantity of Diclofenac Sodium in different areas.


Diclofenac Sodium


Maninagar 1325.00

BAPUNAGAR 825.00

Kankaria 210.00

ODHAV 190.00

Amraiwadi 110.00

VASTRAL 45.00

Diclofenac Sodium Total 4210.00

53

Quantity sold (monthly) of Diclofenac Sodium in different areas. Highest quantity of

Diclofenac Sodium is sold in Meghani nagar while Maninagar, Bapunagar, Kankaria and


Total quantity of Multivitamin Infusion in different areas.


Multivitamin Infusion


Maninagar 1185.00

BAPUNAGAR 460.00

Kankaria 215.00

Amraiwadi 210.00

VASTRAL 100.00

ODHAV 90.00

C.T.M 60.00


54

Quantity sold (monthly) of Multivitamin Infusion in different areas. Highest quantity of

Multivitamin Infusion is sold in Meghani nagar while Maninagar, Bapunagar, Kankaria and


Total quantity of Ondasetron in different areas.


Ondansetron

BAPUNAGAR 1245.00

Maninagar 885.00


C.T.M 175.00

Kankaria 120.00

VASTRAL 81.00

ODHAV 65.00

Amraiwadi 50.00


55

Quantity sold (monthly) of Ondasetron in different areas. Highest quantity of

Ondasetron is sold in Bapunagar while Maninagar, Meghani nagar, C.T.M and


MOLECULES – HOSPITALS – QUANTITY

Total quantities (monthly) sold of Ranitidine according to Hospitals.

MOLECULE HOSPITAL QUANTITY

Ranitidine


Civil Hos 1440.00

Kakdiya Hos 1430.00




Matruchhaya 130.00


56

Quantity sold (monthly) of Ranitidine in different Hospitals. Highest quantity of Ranitidine

sold in L.G.Hospital nearby area while other Hospitals follow it up.

57

Total quantities(monthly) sold of Vitamin B-Complex according to Hospitals.


Vitamin B-Complex

Civil Hos 1780.00


Kakdiya Hos 735.00



Matruchhaya 110.00

Vitamin B-Complex Total 4455.00

Quantity sold (monthly) of Vitamin B-Complex in different Hospitals. Highest quantity of

Vitamin B-Complex sold in Civil Hospital nearby area while other Hospitals follow it up.

58

Total quantities (monthly) sold of Diclofenac Sodium according to Hospitals.


Diclofenac Sodium

Civil Hos 1505.00


Kakdiya Hos 825.00



Matruchhaya 45.00


Quantity sold (monthly) of Diclofenac Sodium in different Hospitals. Highest quantity of

Diclofenac Sodium sold in Civil Hospital nearby area while other Hospitals follow it up.

59

Total quantities (monthly) sold of Multivitamin Infusion according to Hospitals.



Civil Hos 1620.00


Kakdiya Hos 460.00


Matruchhaya 100.00




Quantity sold (monthly) of Multivitamin Infusion in different Hospitals. Highest quantity of

Multivitamin Infusion sold in Civil Hospital nearby area while other Hospitals follow it up.

60

Total quantities of Ondasetron according to Hospitals.


Ondansetron

Kakdiya Hos 1245.00

L.G.Hospital 930.00

Civil Hos 760.00



Matruchhaya 81.00



Quantity sold (monthly) of Ondasetron in different Hospitals. Highest quantity of Ondasetron

sold in Kakdiya Hospital, Bapunagar nearby area while other Hospitals follow it up.

61

COMPETITORS’ SCENARIO

Sr. No. MOLECULES BRANDS COMPANIES

1 Ranitidine

Aciloc CADILA

Rantac J.B.C

Zantac Dr. REDDY

Ranitin TORRENT

2Vitamin B-Complex

Nerobion MERCK

Polybion MERCK

Vitneurin GSK

Dainapar TROIKAA

3 Diclofenac Sodium

Diclonec LUPIN

Vovaran NOVARTIS

Dicloran J.B.C

Diclozecic TORRENT

Emeset CIPLA

4 Ondansetron

Ondem ALKEM

Periset IPCA

Vomikind MANKIND

Zofar SUN

Stean STRONCH

Vomiset INDI PHARMA

Ontic CORONA

Emset CIPLA

5 Multivitamin Infusion

Vitcofol FDC

MVI USV

Optinuron LUPIN

Nurokind MANKIND

Nervic UNIMARCK

Nervizen UNIMARCK

Eldervit ELDER

62

Schemes for molecules in particular area and quantity being sold under

those schemes:

MOLECULES AREA SCHEME

QUANTITY

(MONTHLY)

Ranitidine

Maninagar

No Scheme 825.00

10+1 530.00

20+1 140.00

9+1 40.00


Meghani nagar

No Scheme 1150.00

20+1 110.00

5+1/2 100.00

10+1/2 80.00


BAPUNAGARNo Scheme 1050.00

20+1 380.00


Amraiwadi

No Scheme 245.00

15+1 30.00

20+1 30.00

5+1 25.00


ODHAVNo Scheme 215.00

10+2 15.00

ODHAV Total 230.00

Kankaria

No Scheme 150.00

20+1 50.00

9+1 30.00


C.T.M No Scheme 150.00

C.T.M Total 150.00

63

VASTRAL10+1 70.00

No Scheme 60.00



Vitamin B-Complex

Meghani nagar

No Scheme 1630.00

20+1 100.00

10+1/2 50.00


ManinagarNo Scheme 750.00

20+1 535.00


BAPUNAGAR

No Scheme 435.00

10+1 160.00

20+2 120.00

20+1 20.00


KankariaNo Scheme 165.00

20+1 80.00


Amraiwadi No Scheme 180.00


ODHAV No Scheme 120.00

ODHAV Total 120.00

VASTRAL No Scheme 110.00


Vitamin B-Complex

Total 4455.00

Diclofenac Sodium Meghani nagar No Scheme 1275.00

10+1 130.00

Net 50.00

20+1 50.00

64


Maninagar No Scheme 1135.00

5+1/2 100.00

10+1 90.00



10+1 45.00


KankariaNo Scheme 140.00

10+1 70.00


ODHAV

No Scheme 125.00

9+1 55.00

10+1 10.00

ODHAV Total 190.00

AmraiwadiNo Scheme 60.00

20+2 50.00



VASTRAL Total 45.00



Meghani nagar

No Scheme 1400.00

20+1 120.00

10+1 50.00

25+1 50.00


Maninagar

No Scheme 1015.00

20+1 150.00

10+1 20.00


BAPUNAGAR No Scheme 460.00

65


Kankaria No Scheme 215.00







ODHAV Total 90.00

C.T.M No Scheme 60.00

C.T.M Total 60.00


Total 3940.00

Ondansetron


4+1 20.00


Maninagar

No Scheme 485.00

10+1 250.00

5+1 100.00

9+1 50.00


Meghani nagarNo Scheme 730.00

9+1 30.00


C.T.MNo Scheme 140.00

5+1 35.00

C.T.M Total 175.00

Kankaria No Scheme 120.00


VASTRAL5+1 30.00

10+4 25.00

66

No Scheme 21.00

4+1 5.00

VASTRAL Total 81.00


4+1 20.00

4+2 15.00

10+1 10.00

ODHAV Total 65.00




67

ASSUMPTION

In this study it is assumed that the entire population of retailers selling different

injectable drugs is represented by the selected sample.

LIMITATION

Survey does not include the Hospital Pharmacy.

Quantity values are approximate and it does not indicate the actual number.

In particular area no. of medicals responded are less than the actual no. of medicals

present in area.

Total sample size is only 137 for East zone.

68

CONCLUSION Conclusion form the sample surveyed to understand the movement of most movable

Injectable molecule ;

BASED ON POTENTIAL

From the Survey,

► Amoxicillin + Clavulanic Acid has the highest potentials, while Amikacin

Sulphate, Pantoprazole, Ondansetron, Multivitamin Infusion follow it up

respectively.

No. Molecules Potential (Rs.) Quantity(Monthly

)

No. of

Competitor

Brands

1 Amoxicillin + Clavulanic

Acid

220472.62 1647 4

2 Amikacin Sulphate 161506.23 2677 4

3 Pantoprazole 92967.00 1590 3

4 Ondansetron 89129.48 3381 8

5 Multivitamin Infusion 54146.16 3940 7

69

Graph shows the percentage share of 5 Molecules having the highest potential. Amoxicillin +

Clavulanic acid has the highest percentage share while other molecules follow it up.

70

BASED ON VOLUME (No. OF QUANTITY SOLD PER MONTH)

► Ranitidine has the highest no. of quantity sold per month while Vitamin B-Complex,

Diclofenac Sodium, Multivitamin Infusion, Ondansetron follow it up respectively.

Sr.

No.

MOLECULES QUANTITY

(MONTHLY)

POTENTIAL

(Rs.)

No. OF

COMPETITOR

BRANDS

1 Ranitidine 5475.00 17439.15 4

2 Vitamin B-Complex 4455.00 18955.85 4

3 Diclofenac Sodium 4210.00 41084.25 5

4 Multivitamin Infusion 3940.00 54146.16 8

5 Ondansetron 3381.00 89129.48 7

71

Percentage share of Molecules in terms of Quantity(Monthly). Ranitidine has the highest

percentage (In terms of Quantity) while Vitamin B-Complex, Diclofenac Sodium,

Multivitamin Infusion, Ondasetron and others follow it up respectively.

72

RECOMMANDATION

From the Report and Analysis of Data, I would suggest five molecules with respect two

different view.

To gain the potential in new molecules, I would recommend the company to go with

the five molecules having the highest potential. They are ;

Amoxicillin + Clavulanic Acid

Amikacin Sulphate

Pantoprazole


Ondasetron respectively.

To build up money rotation, I would suggest company to go with the molecules which

are sold in highest quantity per month. They are ;

Ranitidine

Vitamin B-Complex

Diclofenac sodium


Ondasetron respectively.

73

BIBLIOGRAPHY

BOOKS

Drug Today (January – March 2009)

IDR

Elements Of Pharmacology (By R.K.Goyal & Anita Mehta)

WEBSITES

www.clarislifesciences.com

www.evaluatepharma.com

www.pharmaceutical-technology.com

www.pharmafocusasia.com

www.worldpharmanews.com

economictimes.indiatimes.com

www.pharmainfo.com

www.pharmaworld.com

74

http://www.pharmainfo.com/

http://www.worldpharmanews.com/

http://www.pharmafocusasia.com/

http://www.pharmaceutical-technology.com/

http://www.evaluatepharma.com/

http://www.clarislifesciences.com/

ANNEXURE

QUESTIONNAIRE

75

Documents

Research on injection in ahmedabad